• Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Helix BioMedix Inc

  • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Disease Focus
    • DNA Damage Response (DDR)
    • Xeroderma Pigmentosum
  • Programs
    • Pharma
    • Personal Care
  • News
    • Press Releases
    • Presentations
    • Scientific Publications
  • Investors
    • Stock Information
    • IR Updates
    • Proxy
    • Corporate Governance
  • Contact Page
You are here: Home / Investors / Corporate Governance

Corporate Governance

The Management and Board of Directors of Helix BioMedix Inc. are committed to operating the company in an efficient, compliant and ethical manner, thereby improving our ability for growth and creation of value for our stockholders.

The following documents represent Helix BioMedix’s commitment to strong corporate governance and business ethics.

Amended & Restated Certificate of Incorporation [pdf]
Corporate Bylaws [pdf]
Code of Conduct [pdf]
Code of Ethics [pdf]
Whistle Blowing Policy [pdf]
Charter for the Governance Committee [pdf]
Charter for the Audit Committee [pdf]
Charter for the Compensation Committee [pdf]

Primary Sidebar

Footer

COMPANY PROFILE

Helix BioMedix is a biopharmaceutical company focused on drug development for treatment of rare dermatological diseases, such as xeroderma pigmentosum.  Our legacy R&D consists of an extensive proprietary library of patented bioactive peptides based on the body’s innate immunity.

 

 

 

 

Terms & Conditions | Privacy Policy

Search

 

©2023 HELIX BIOMEDIX, INC.
ALL RIGHTS RESERVED

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter

Copyright © 2025 · Executive Pro On Genesis Framework · WordPress · Log in